We aimed to evaluate the value of immunohistochemical markers and serum CA125 in predicting the risk of lymph node metastasis (LNM) in women with endometrial cancer and to identify a low-risk group of LNM. The gene discussed is MUC16; the disease is metastatic malignant neoplasm in the lymph nodes.